A Phase 2a, Randomized, Placebo-Controlled Human Challenge Trial to Evaluate the Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated with Respiratory Syncytial Virus

Abstract Introduction Human respiratory syncytial virus (RSV) infections can result in hospitalization and/or death among vulnerable populations. Molnupiravir is a prodrug of ß-D-N4-hydroxycytidine, which has broad-spectrum preclinical activity against RNA viruses. We conducted a pilot trial evaluat...

Full description

Bibliographic Details

Published in:	Pulmonary Therapy
Main Authors:	Mickie H. Cheng, Alex J. Mann, Brian M. Maas, Tian Zhao, Melissa Bevan, Andrea K. Schaeffer, Laura E. Liao, Andrew P. Catchpole, David W. Hilbert, S. Aubrey Stoch, Carisa S. De Anda
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2025-04-01
Subjects:	RSV Antiviral Clinical trial hVCM Human challenge Molnupiravir
Online Access:	https://doi.org/10.1007/s41030-025-00289-z